Allena Pharmaceuticals, Inc.

87 articles with Allena Pharmaceuticals, Inc.

• Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

  4/7/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.

• Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/9/2021

  -- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout -- -- Management team strengthened with addition of David Clark, M.D., M.R.C.P as Chief Medical Officer and Richard Katz, M.D. as Chief Financial Officer -- NEWTON, Mass., March 09, 2021

• Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

  2/24/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March: Cowen’s 41 st Annual Health Care Conference

• Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

  2/2/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO), effective immediately

• Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

  1/4/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January:

• 

  Clinical Catch-Up: November 30-December 4

  12/7/2020

  It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.

• Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

  12/2/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares

• Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

  12/1/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of David J. Clark, M.D., M.R.C.P, as Chief Medical Officer, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an

• Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

  12/1/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC

• Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346

  11/30/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers

• Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

  11/24/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference

• Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

  11/9/2020

  Presented Data at 53rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in Enteric Hyperoxaluria (EH)

• Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November

  11/3/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November

• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors

  10/5/2020

  Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Ann Miller, M.D., to its board of directors. “Ann is an experienced and successful industry executive, who has built multiple high-performing commercial teams and successfu

• Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

  9/30/2020

  - Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into a $25 million convertible debt financing a

• Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney DiseaseInitial Data Expected in the Fourth Quarter of 2020

  9/8/2020

  Allena Pharmaceuticals, Inc., a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced that the first subject has been dosed in a Phase 1 clinical trial of ALLN-346.

• Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September

  9/3/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September: Baird 2020 Global Healthcare Conference Date: Thursday, September 10 Time: 9:40 a

• Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

  8/5/2020

  -- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –- -- Raised Gross Proceeds of $22.7M Through Two Public Offerings, Extending Cash Runway Beyond the Second Quarter of 2021 –-

• Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/4/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 202